Key Highlights

  • A proposed USD 150.0 million underwritten offering, with an option of up to USD 22.5 million exercisable within 30 days, accompanied SELLAS Life Sciences (NASDAQ:SLS) shares falling 13.98% on Thursday, November 19, 2026.
  • ClearOne (NASDAQ:CLRO) declined 11.59% once it wrapped up a USD 4.00 per share Placement of 999,999 shares on November 17, 2026, bringing its outstanding share total to 3,675,411.
  • PepGen (NASDAQ:PEPG) gained 8.82% despite a 25 million share sale that set its price at USD 5.00 on November 11, 2026, a transaction meant to deliver roughly USD 125 million before fees.
  • newcleo (NASDAQ:NWCL) fell 6.9% in the wake of a November 18, 2026 prospectus supplement that could register up to 217,834,936 ordinary shares, equal to around 77% of outstanding stock (calculated).

SELLAS Life Sciences (NASDAQ:SLS): Dilution Arrives Soon After a Late-Stage Win

Shares of SELLAS Life Sciences (NASDAQ:SLS) dropped 13.98% during midday trading on Thursday, November 19, 2026, so the prior close can be derived at roughly USD 17.95 (calculated). Earlier, on November 17, 2026, the REGAL Phase 3 trial of galinpepimut-S in acute myeloid leukemia achieved a success on overall survival, with median survival at 24.0 months versus 14.7 months on best available therapy. That same day the company introduced a proposed public offering of USD 150.0 million, where J.P. Morgan and TD Cowen act as joint book-running managers, and underwriters can add up to USD 22.5 million more within a month. Every share on offer is issued by the company, so ownership is diluted across a larger base. Neither a per-share price nor a use of proceeds has been disclosed, and no final pricing has been verified. Cash stood at USD 134.7 million at the end of September 2026, while the third-quarter net loss was USD 10.1 million. A discussion with the FDA about an accelerated filing route is planned, and a Biologics License Application, slated for the first half of 2027, is being readied. Watch-points include an open-label design with 126 patients, a p-value of 0.035 that falls only a little under the 0.05 benchmark, and offering terms that are not assured. No other corporate announcement was identified, so dilution is the most probable cause, though it has not been confirmed.

ClearOne (NASDAQ:CLRO): Placement at USD 4.00 and a Pending Listing Hearing

ClearOne (NASDAQ:CLRO) lost 11.59% on November 19, 2026, even though the prior close was about USD 6.90 (calculated), which is far above the USD 4.00 placement price. A sale of 999,999 shares at USD 4.00 was completed on November 17, 2026 for total proceeds of USD 3,999,998. Before expenses, roughly USD 2.756 million was received in cash, and the largest holder, First Finance, exchanged USD 1,244,458 owed to it, interest included, for 311,114 shares. Post-deal, the company has 3,675,411 shares outstanding, and the new stock accounts for around 27% of that figure (calculated). The raise is connected to an exchange issue: On October 8, 2026, Nasdaq staff ruled that the company fell short of the USD 2.5 million minimum Equity test, and a hearing was booked for November 17, 2026. Management submitted pro forma equity of USD 3.282 million, described as preliminary and unaudited, and audit adjustments or further losses could push it lower. Nasdaq has not yet confirmed that the deficiency is resolved. Published reporting also mentioned zero continuing Revenue and a Merger underway with Cortigent and Vivani Medical, but neither point is confirmed here. No separate company statement accompanied the move, and with so few shares outstanding, a small number of trades can shift the price.

PepGen (NASDAQ:PEPG): Advance Stalls Short of the Offering Price

PepGen (NASDAQ:PEPG) rose 8.82% to USD 4.16 on November 19, 2026, yet the shares still trail the USD 5.00 deal price by about 16.8%, a gap derived from simple arithmetic on two published figures. That made it the single advancer in this four-company set. On November 11, 2026, the company placed 25 million shares through underwriters at USD 5.00 each, which would bring in USD 125 million before fees, and the underwriters hold a 30-day right to buy as many as 3.75 million more. Phase 2 results for PGN-EDODM1, a candidate aimed at myotonic dystrophy type 1, preceded the offering, with the 10 mg/kg dose producing a mean splicing correction of 46.5%. At September 30, 2026, the company held USD 104.8 million in cash, and including the gross proceeds the company would hold about USD 229.8 million before expenses and later outlays (calculated). The third quarter ended with a net loss of USD 19.4 million. The chief risk is a partial clinical hold from the FDA dating to March 2026, and a planned regulatory meeting hinges on lifting it. Searches uncovered no company news for November 17 to 19, so the rise cannot be linked to a new development, and the offering's closing remains unconfirmed.

newcleo (NASDAQ:NWCL): Registration Filing Lands Beside a Larger Cash Pile

newcleo (NASDAQ:NWCL) was lower by 6.9% on November 19, 2026, with the implied previous close at USD 3.77 (calculated), beneath the USD 4.01 close on November 17. Its third-quarter update came out on November 18, 2026, together with a prospectus supplement that could register up to 217,834,936 ordinary shares and another 9,146,717 shares connected to warrants. Outstanding shares were 281.5 million on September 30, 2026. The filing does not show an offering price, and the reviewed excerpt did not identify its purpose, though this kind of registration typically lets existing holders sell. No new financing was disclosed. The cash balance reached 233.4 million euros, versus 90.4 million euros twelve months earlier, while product and service revenue advanced about 26%, reaching 9.95 million euros. On September 22, 2026, a lead-cooled reactor developer obtained its Nasdaq listing by merging with a blank-check firm. Risks cover a large amount of registered stock hitting the market, slender revenue against heavy Capital requirements, slippage in the schedule for its Italian demonstrator and licensing. Searches did not surface any company release that accounts for the slide, and cheap shares can carry wide spreads.

Where Things Stand

The USD 150 million offering does not fully explain the divergent results. SELLAS Life Sciences (NASDAQ:SLS) shed 13.98%, the sharpest drop in the group. ClearOne (NASDAQ:CLRO) receded 11.59% following a USD 4.00 placement that increased its share count by about 27%. newcleo (NASDAQ:NWCL) gave back 6.9% alongside a resale filing that provides no new capital. PepGen (NASDAQ:PEPG) added 8.82% but still trades under its USD 5.00 offering price. Just two of the four are linked to a share sale that the company clearly announced and dated to the same trading day, and none of the companies has confirmed what drove the moves. Future checkpoints include the final SELLAS pricing, the Nasdaq panel ruling on ClearOne, the closing of the PepGen transaction and any holder sales under the newcleo filing. None of these items promises further movement.